Vogenx Inc Common Stock Total Assets
Vogenx Inc Common Stock total assets. Based on the latest financial reports, Vogenx Inc Common Stock (VOGX) holds total assets worth $1.41 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Vogenx Inc Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Vogenx Inc Common Stock (2024–2025)
Total assets of Vogenx Inc Common Stock from 2024 to 2025. This chart illustrates how Vogenx Inc Common Stock's total assets have evolved over time, based on quarterly financial data. See Vogenx Inc Common Stock stock price for real-time trading data and today's change.
Vogenx Inc Common Stock - Asset Composition Analysis
Vogenx Inc Common Stock Total Assets Breakdown (December 2025)
Vogenx Inc Common Stock total assets breakdown as of December 2025. Vogenx Inc Common Stock's total assets of $1.41 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Vogenx Inc Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Vogenx Inc Common Stock short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vogenx Inc Common Stock's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2024.
- Cash Position: Cash and equivalents constituted 88.2% of total assets in 2025, down from 99.2% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Vogenx Inc Common Stock Competitors by Total Assets
Key competitors of Vogenx Inc Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
Vogenx Inc Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.44 | 0.39 | - |
| Quick Ratio | 0.44 | 0.39 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $-1.78 Million | $-1.40 Million | - |
Vogenx Inc Common Stock - Advanced Valuation Insights
This section examines the relationship between Vogenx Inc Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 381.43 |
| Asset Growth Rate (YoY) | -29.8% |
| Total Assets | $681.17K |
| Market Capitalization | $259.82 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Vogenx Inc Common Stock's assets at a significant premium (381.43x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Vogenx Inc Common Stock's assets decreased by 29.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vogenx Inc Common Stock (2024–2025)
The table below shows the annual total assets of Vogenx Inc Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $681.17K | -29.81% |
| 2024-12-31 | $970.40K | -- |
About Vogenx Inc Common Stock
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party pay… Read more